<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>One hundred and sixty four patients with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> in remission were entered into a double blind, double dummy trial comparing olsalazine 500 mg bd and sulphasalazine 1 g bd </plain></SENT>
<SENT sid="1" pm="."><plain>Clinical examination, sigmoidoscopy and rectal biopsy were performed at 0, three, and six months </plain></SENT>
<SENT sid="2" pm="."><plain>Sixteen of 82 (19.5%) patients relapsed on olsalazine and 10/82 (12.2%) relapsed on sulphasalazine </plain></SENT>
<SENT sid="3" pm="."><plain>The difference was not statistically significant (p = 0.1632) </plain></SENT>
<SENT sid="4" pm="."><plain>Adverse events were minor and were similar in both groups </plain></SENT>
<SENT sid="5" pm="."><plain>No haematological or biochemical abnormalities were detected </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, olsalazine is as effective as sulphasalazine for preventing a relapse of <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> </plain></SENT>
</text></document>